囊肿纤维化市场：预测（2024-2029）

2022 年囊肿纤维化市场价值为 9,291,199,000 美元。

产生黏液、汗水和消化液的细胞受到囊肿纤维化的影响。分泌物会堵塞而不是润滑管道、导管和通道，尤其是在胰臟和肺部。由于囊肿纤维化的生长需要两个不同基因的突变，因此囊肿纤维化在家族中遗传，并且该疾病被认为是隐性遗传的。

囊肿纤维化市场推动要素

产业对研发研究投资的增加，以及治疗领域其他技术的发展，将为产业参与者创造新的成长机会。穿戴式感测器由美国国立卫生研究院的研究人员创建，用于帮助诊断和追踪疾病的发作。该感测器可以检测患者体内任何异常的盐平衡，并以无线方式发送讯息进行测试。在整个预测期内，由于治疗这种疾病的新治疗方法和药物开发的技术创新不断增加，囊肿纤维化市场预计将成长。

囊肿纤维化普及不断扩大

根据囊肿纤维化基金会 2022 年发布的最新估计，过去十年中，囊肿纤维化患者的数量增加。美国约有 40,000 名儿童和成人患有囊肿纤维化，全球估计有 105,000 人被诊断出患有囊性纤维化，这推动了囊肿纤维化市场的发展。 2012 年，美国患有 CF 的人数估计超过 30,000 人，全球患有 CF 的人数超过 70,000 人。我们使用囊肿纤维化基金会患者登记处和美国人口统计数据来计算囊性纤维化患者总数的最新估计值。

CFTR 越来越受欢迎

人体的氯离子通道、跨膜电导调节蛋白 (CFTR) 有助于控制钠和氯离子进出肺部和其他器官的细胞膜。 CFTR 调节剂可减少肺部突发事件和呼吸道症状，同时改善细胞体功能并改善患者的生活品质。囊肿纤维化市场的最大份额预计属于 CFTR 药物。此外，尖端治疗方法的增加，包括 CFTR 调节剂的三重联合治疗，预计将推动业务发展。

来自主要企业的各种产品创新

随着囊性纤维化治疗药物即将推出，囊肿纤维化市场正在扩大。在预期期间，针对囊性纤维化患者细胞缺陷的药物的推出以及此类药物改变许多人生活的潜力预计将推动囊肿纤维化市场的扩张。此外，推动囊肿纤维化市场的主要因素被认为是该疾病盛行率的不断增加。这正在加速最近发现的治疗重症患者所需的管道药物的上市。

政府倡议增多

政府正努力为囊肿纤维化患者提供治疗机会，从而增加对囊肿纤维化领域产品的需求。例如，2023 年 4 月，Trikafta（elexacaftor、tezacaftor、ivacaftor）透过药物福利计画（PBS）可供 6 至 11 岁囊肿纤维化患者使用。囊肿纤维化患者及其家人的生活预计将因针对该特定年龄层的 Trikafta 的推出而受到重大影响。家庭可以透过 PBS 获得 Trikafta，每次处方笺价格高达 30 美元，6 至 11 岁儿童可透过特许经营卡获得 7.30 美元，从而支持囊肿纤维化市场在整个预期期间的成长。

活性化市场研发

市场收益的扩张主要是由治疗研发投资的增加所推动的。例如，2023年1月，旨在重塑基因疗法的Gensaic公司宣布已获得囊肿纤维化基金会的资助，用于研究该疾病的基因疗法。囊肿纤维化患者数量的增加、对替代疗法的需求不断增长以及更复杂药物的研发进展是推动囊肿纤维化市场收益成长的一些关键因素。

囊肿纤维化市场的临床试验增加

由于各种治疗方法的出现，囊肿纤维化市场正在扩大。雾化抗生素给药可减少慢性肺病患者的肺损伤并增强肺功能。阿奇霉素 FEV1 治疗的随机对照试验表明，可减少病情加重并改善生活品质。此外，2023 年 6 月，一种革命性的囊肿纤维化新治疗方法将进入临床试验。这种有前途的可吸入分子假体是由伊利诺大学香槟分校卡尔伊利诺医学院和爱荷华大学卡弗医学院的研究人员与衍生生物技术公司 Cystetic Medicines 合作开发的。其目的是改善对现有治疗方法无反应的囊性纤维化患者的肺功能。

在北美，囊肿纤维化市场预计将稳定成长。

在北美地区，由于囊肿纤维化盛行率不断上升以及该地区可用的治疗方法种类繁多，囊肿纤维化市场占有率预计将保持相当大的规模，预计将显着扩大。透过增加用于治疗囊肿纤维化的药物研发研究的资金以及其他有益的政府倡议，将促进囊肿纤维化区域市场的扩大。囊肿纤维化社群现在可以透过北美囊肿纤维化会议 (NACFC) 提供的教育论坛讨论研究和开发的最新进展。其他因素，例如囊肿纤维化市场中竞争对手的存在、先进的医疗基础设施和医疗费用预计将刺激囊肿纤维化市场的扩张。

目录

第一章简介

• 市场概况
• 市场定义
• 调查范围
• 市场区隔
• 货币
• 先决条件
• 基准年和预测年时间表

第二章调查方法

• 调查资料
• 先决条件

第三章执行摘要

• 研究亮点

第四章市场动态

• 市场驱动因素
• 市场限制因素
• 波特五力分析
• 产业价值链分析

第五章囊肿纤维化市场：依药物类别

• 介绍
• CFTR调变
• 黏液溶解剂
• 支气管扩张剂
• 其他的

第六章囊肿纤维化市场：依给药途径

• 介绍
• 口服
• 胃肠外的

第七章囊肿纤维化市场：按分销管道

• 介绍
• 医院
• 零售药房
• 其他的

第八章囊肿纤维化市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争环境及分析

• 主要企业及策略分析
• 市场占有率分析
• 合併、收购、协议和合作

第十章 公司简介

• Vertex Pharmaceuticals
• Pfizer
• Spirovant
• Mayo Clinic
• Evaluate Pharma
• Krystal Biotech
• Kalydeco
• Sionna Therapeutics
• Chiesi Cystic Fibrosis
• Verona Pharma

The cystic fibrosis market was valued at US$9,291.199 million in 2022.

The cells that make mucus, perspiration, and digestive fluids are impacted by cystic fibrosis. The secretions clog up tubes, ducts, and passages rather than lubricating them, particularly in the pancreas and lungs. Cystic fibrosis runs in families because cystic fibrosis requires two different gene variations to grow, the ailment is considered to be recessive.

Driving factors for the cystic fibrosis market

Increasing industry investment in R&D research along with other technical developments in the therapeutic field creates new growth opportunities for industry participants. A wearable sensor was created by NIH researchers to aid in the diagnosis and tracking of illness development. The sensor picks up the patients' bodies' abnormal salt balance and wirelessly transmits the information for examination. Throughout the forecast period, it is predicted that the cystic fibrosis market will grow due to increased innovation in the creation of novel treatments and pharmaceutical products to treat the condition.

Growing prevalence of cystic fibrosis

According to a recent estimate by the Cystic Fibrosis Foundation published in 2022, the number of people with cystic fibrosis has grown over the previous ten years. Nearly 40,000 children and adults suffer from cystic fibrosis in the United States, while an estimated 105,000 people worldwide have received a CF diagnosis fueling the cystic fibrosis market. The number of individuals with CF was last estimated to be over 30,000 in the United States and 70,000 worldwide in 2012. The Cystic Fibrosis Foundation Patient Registry and the Vital Statistics of the United States were used to get the most recent estimate of the overall number of CF patients.

Growing popularity for CFTR

As a chloride channel in the body, the transmembrane conductance regulator (CFTR) protein aids in controlling the movement of sodium and chlorine into and out of the cell membranes of the lungs and other organs. CFTR modulators improve cellular body function and patients' quality of life while reducing lung flare-ups and respiratory symptoms. The cystic fibrosis market's largest share is anticipated to belong to CFTR medications. Additionally, the development of the business will be fueled by additional cutting-edge treatments including triple combination medications with CFTR modulators.

Various product innovations by key players

The cystic fibrosis market is expanding due to the impending launch of medications for the treatment of CF. During the anticipated period, cystic fibrosis market expansion will be aided by the introduction of medications that target the faults in diseased people's cells and the likelihood that the medications will change the lives of many people. Additionally, it is believed that growth in the disease's prevalence is the main factor driving the cystic fibrosis market. This is speeding up the launch of recently discovered pipeline drugs required for the treatment of critically ill patients.

Increase in government initiatives

Through its efforts to provide access to therapies for those who have cystic fibrosis, the government is seeking to increase demand for products in the cystic fibrosis sector. For instance, in April 2023, Trikafta (elexacaftor, tezacaftor, ivacaftor, and ivacaftor) was made available via the Pharmaceutical Benefits Scheme (PBS) for cystic fibrosis patients between the ages of 6 and 11 years old. Cystic fibrosis patients and their families' lives are anticipated to be significantly affected by the advent of Trikafta for this particular age range. Families can get Trikafta through PBS for a maximum price of $30 per prescription or $7.30 with a concession card for children aged 6 to 11, fuelling the cystic fibrosis market growth throughout the anticipated timeframe.

Rising research & development in the market

Growing market revenue is mostly being driven by rising therapeutic R&D investments. For instance, in January 2023, Gensaic, a business that wants to reinvent gene therapy, announced that it has received money from the Cystic Fibrosis Foundation to research a gene therapy for the disease. The rising frequency of cystic fibrosis patients, higher demand for alternative therapies, and ongoing research & development of more sophisticated drugs are some of the main factors propelling revenue growth in the cystic fibrosis market.

Increasing clinical trials in the cystic fibrosis market

The cystic fibrosis market is expanding as a result of a range of treatments available. Nebulized antibiotic therapy lowers lung damage and enhances lung function in patients with chronic lung disease. A randomized controlled study of azithromycin FEV1 therapy shows a decrease in exacerbations and an improvement in quality of life. Further, in June 2023, a potentially ground-breaking new therapy for cystic fibrosis is currently undergoing clinical testing. This promising inhalable molecular prosthetic was developed by researchers at the Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign and the Carver College of Medicine at the University of Iowa in collaboration with the spin-out biotechnology company, Cystetic Medicines. It aims to improve lung function in CF patients who are not responding to existing treatments.

In North America, it is projected that the cystic fibrosis market will grow steadily.

The North American region is anticipated to secure a sizable cystic fibrosis market share and is anticipated to expand significantly during the predicted period due to the rising prevalence of cystic fibrosis and the wide range of available treatments in the area. Regional cystic fibrosis market expansion will be fueled by increased financing for research and development studies on medications for cystic fibrosis and other beneficial government initiatives. The cystic fibrosis community can now discuss the most recent advancements in R&D due to educational forums offered by the North American Cystic Fibrosis Conference (NACFC). Other elements, including the existence of significant cystic fibrosis market competitors, a sophisticated healthcare infrastructure, and reimbursements, are anticipated to fuel cystic fibrosis market expansion.

Market Key Developments

• In September 2022, the multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer can use CytoReason's AI technology in its drug development initiatives.
• In July 2022, The Cincinnati Children's Hospital Medical Centre announced a partnership with the Boomer Esiason Foundation (BEF) and the research intelligence firm Epistemic AI that will enable the division of pulmonary medicine to use artificial intelligence (AI) to speed up clinical research on cystic fibrosis and respiratory diseases.
• In April 2022, The Bakar BioEnginuity Hub's incubator, Bakar Labs, and the Cystic Fibrosis Foundation jointly launched the first-ever "Golden Ticket" Competition to find the next promising cystic fibrosis drug.

Segmentation:

By Drug Class

• CFTR Modulators
• Mucolytics
• Brochodilators
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital
• Retail Pharmacies
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. CYSTIC FIBROSIS MARKET, BY DRUG CLASS

• 5.1. Introduction
• 5.2. CFTR Modulators
• 5.3. Mucolytics
• 5.4. Brochodilators
• 5.5. Others

6. CYSTIC FIBROSIS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Oral
• 6.3. Parenteral

7. CYSTIC FIBROSIS MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital
• 7.3. Retail Pharmacies
• 7.4. Others

8. CYSTIC FIBROSIS MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

• 10.1. Vertex Pharmaceuticals
• 10.2. Pfizer
• 10.3. Spirovant
• 10.4. Mayo Clinic
• 10.5. Evaluate Pharma
• 10.6. Krystal Biotech
• 10.7. Kalydeco
• 10.8. Sionna Therapeutics
• 10.9. Chiesi Cystic Fibrosis
• 10.10. Verona Pharma